Bristol Myers' stock decline in response to weak guidance is a gift to investors – CNBC
The Bristol-Myers Squibb on Thursday reported quarterly results that exceeded expectations, but the 2025 guidance sent stocks low. Jim Cramer's faith in drug makers is unshakable. Analyst estimates compiled by LSEG show revenue for the fourth quarter increased 8% year-on-year to $12.34 billion, well above the $11.57 billion consensus. LSEG data shows an adjustment of […]